Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

Baseline Clinical Characteristics as defined by baseline patient clinical characteristics (e.g. medical history, comorbidity, potential professional exposure, past history of cancer or auto-immune disease, smoking status, NSCLC or SCLC characteristics)

OS is defined as the time from date of initiation of treatment combination initiation to date of death from any cause. Patients alive (or lost to follow up) at the time of analysis will be censored at the date they were last known to be alive.

ORR is defined as the proportion of patients with complete response (CR) or partial response (PR) as the best response during the study according to RECIST 1.1 criteria based on tumoral assessment performed by the investigator using thorax-abdominal-pelvic and brain CT scans. The frequency of the tumor assessments will follow the site practices.

ORR is defined as the proportion of patients with complete response (CR) or partial response (PR) as the best response during the study according to RECIST 1.1 criteria based on tumoral assessment performed by the independent panel based on thorax-abdominal-pelvic and brain CT scans provided by the sites.

All adverse events experienced by the participants, whatever the grades of toxicity, will be collected according to CTCAE v5.0 (common terminology criteria for adverse events).

Treatment duration as defined from the date of the first dose of of chemotherapy and amivantamab combination up to the date of the last dose of the combination received by the patient.

Reason for discontinuation is defined by the reason for permanent discontinuation of combination treatment as recorded by the investigator (e.g. : disease progression, adverse event, lack of efficacy, patient decision, physician decision, other)

Site of disease progression after combination therapy is defined as the anatomical site(s) of first documented disease progression occurring after initiation of the combination treatment, as assessed by the investigator according to the study specified response criteria (e.g., RECIST, disease specific criteria). The site of progression will be categorized (e.g., target lesions, non target lesions, new lesions; organ specific sites such as lung, liver, bone, CNS, lymph nodes, primary tumor, etc.).

Post-progression treatments received after documented disease progression will be collected and categorized. Data will include the type of therapy administered (e.g., systemic anticancer therapy, radiotherapy, surgery, supportive or palliative care). This measure describes subsequent lines of treatment and supports interpretation of survival outcomes.

Post progression Progression Free Survival is defined as the time from the initiation date of the first post progression systemic anti cancer treatment to the date of the first documented disease progression (per local practice/standard criteria) or death from any cause, whichever occurs first.

Treatment outcomes by patients' baseline and disease characteristics defined as the comparison of :

• Efficacy outcomes (PFS)
• Safety outcomes (incidence and grade of adverse events under treatment) across predefined patient subgroups (e.g., age, performance status, metastatic sites, prior lines of therapy, biomarkers).

Investigator ORR CNS is defined as the proportion of patients with complete response (CR) or partial response (PR) as the best response during the study according to RECIST 1.1 criteria assessed by the investigator based preferentially on tumoral assessment performed by cerebral imaging every 12 weeks on patients with brain metastasis at diagnostic.

Independent Panel ORR CNS is defined as the proportion of patients with complete response (CR) or partial response (PR) as the best response during the study according to RECIST 1.1 criteria assessed by the independent panel based on tumoral assessments performed by the site on patients with brain metastasis at diagnostic.

Investigator PFS CNS is defined as the time between chemotherapy and amivantamab combination treatment initiation date and date of first documentation of disease progression date defined by the Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 progression or death for any cause, whichever comes first.

Disease progression will be evaluated according to (RECIST) 1.1 assessed by the investigator based preferentially on tumoral assessment performed by cerebral imaging every 12 weeks on patients with brain metastasis at diagnostic.

Independent Panel PFS CNS is defined as the time between chemotherapy and amivantamab combination treatment initiation date and date of first documentation of disease progression defined by the Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 progression or death for any cause, whichever comes first.

Disease progression will be evaluated according to (RECIST) 1.1 assessed by the independent panel based preferentially on tumoral assessment performed by cerebral imaging every 12 weeks on patients with brain metastasis at diagnostic.

OS CNS is defined as the time from date of initiation of treatment combination initiation to date of death from any cause on patients with brain metastasis at diagnostic.

Performance status will be assessed at baseline using the validated scale called Eastern Cooperative Oncology Group [ECOG] Performance Status. The measure captures the participant's level of functional impairment and ability to carry out daily activities. Scores will be recorded as defined by the selected scale.

Age of participants will be recorded at baseline. Age will be collected in years. This measure characterizes the study population and supports demographic and subgroup analyses.

Body weight will be collected at baseline. Weight will be recorded in kilograms using a calibrated scale. This measure characterizes the study population and may support safety, dosing, or subgroup analyses.

Body Mass Index (BMI) will be calculated at baseline using measured weight and height. BMI will be expressed in kg/m². This measure characterizes the study population and may support safety, or subgroup analyses.

The number of treatment cycles administered after documented disease progression will be collected for each participant. This measure captures the extent of post-progression therapy and supports interpretation of subsequent treatment exposure.

The duration of each post-progression treatment will be recorded from the start date to the end date of the administered therapy. This measure characterizes the length of exposure to subsequent treatments following documented disease progression.